SudoGest Pseudoephedrine Hydrochloride 30 mg Tablet, 100-count — NDC 00904-6727-60 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

SudoGest Pseudoephedrine Hydrochloride 30 mg Tablet, 100-count — NDC 0904-6727-60 (Billing 00904-6727-60)

by Major Pharmaceuticals · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of SudoGest Pseudoephedrine Hydrochloride 30 mg Tablet from Major Pharmaceuticals, marketed since Jan 2019 and currently FDA-listed; retail pharmacies pay about $0.0776 per tablet (NADAC). It is this product's only package size.

NDC 00904-6727-60
🏷️ FDA NDC (as labeled) 0904-6727-60 billing pads the labeler segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 0904-6727-60 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0904 labeler · 6727 product · 60 package
Package marketed since
Jan 31, 2019
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
100 EA per package
Barcode (UPC-A, from the NDC)
3 0904672760 6
Medicaid fills, this package
1,315 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0904-6727-60
Product NDC 0904-6727
11-digit billing NDC 00904672760
NCPDP billing unit EA — each (per item)
RxCUI 1049160, 1049162
UNII 6V9V2RYJ8N
Application # M012
SPL Set ID 78faa497-6743-b85b-e053-2a91aa0ae822
Established class (EPC) alpha-Adrenergic Agonist
Mechanism of action Adrenergic alpha-Agonists
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-01-31
Route ORAL
Dosage form TABLET
Substance PSEUDOEPHEDRINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 42101020100305
GPI class SudoGest
GCN Seq No 005089
GCN 20481
HICL code 002091
Ingredient (HICL) Pseudoephedrine Hcl
HIC1 code B
Therapeutic class — broad (HIC1) Respiratory System
HIC2 code B6
Therapeutic class — intermediate (HIC2) Drugs Affecting The Trachea And Bronchi (Cont3)
HIC3 code B6V
Therapeutic class — specific (HIC3) Decongestants, Oral
AHFS code 12:12.12.00
AHFS class Alpha- And Beta-Adrenergic Agonists
FDB label name SUDOGEST 30 MG TABLET
FDB brand name Sudogest
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 005089
  • GCN: 20481
  • GPI-14 (Medi-Span): 42101020100305
  • HICL (First Databank): 002091
  • AHFS class code: 12:12.12.00
  • RxCUI (RxNorm): 1049160
Why two NDCs? The FDA registers this code as 0904-6727-60 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00904-6727-60. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the alpha-Adrenergic Agonist class.

Pharmacologic class alpha-Adrenergic Agonist
Drug family (ATC) Sympathomimetics
How it works Adrenergic alpha-Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name SUDOGEST 30 MG TABLET Ingredient Pseudoephedrine Hcl
📗 Our plain-language guide HelloPharmacist
  • It temporarily relieves nasal congestion from the common cold, hay fever or other upper respiratory allergies. Many products also relieve sinus congestion and pressure.
  • It depends on the product. Regular tablets and softgels are usually taken every 4 to 6 hours, while 12-hour extended-release tablets are taken every 12 hours. Check your box for th...
  • No. Swallow them whole. Don't divide, crush, chew or dissolve them. Seeing part of the tablet in your stool can happen and is normal.
  • Can I crush or chew the extended-release tablets?
📖 Read our full Pseudoephedrine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.078 $7.76 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.2622 $26.22 / 100 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.078 $0.048
▲ Up 52% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00904-6727-60 You're viewing this Main listing 100 TABLET in 1 BOTTLE 2019-01-31 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Good Sense Nasal Decongestant 30 mg 00113-0432-62 L. 24 tablets $0.078 — Availability likely —
Nasal Decongestant 30 mg 00536-3607-35 Rugby 24 tablets $0.078 — Availability likely —
SudoGest 30 mg 00904-5053-59 Major 100 tablets $0.078 — Availability likely —
SudoGest Nasal Decongestant 30 mg 00904-6337-24 Major 1 tablet $0.078 — Availability likely —
SudoGest 30 mgthis 00904-6727-60 Major 100 tablets $0.078 — Availability likely —
Pseudoephedrine HCl 30 mg 00904-6990-61 Major 10 tablets $0.078 — Availability likely —
pseudoephedrine hydrochloride 30 mg 45802-0432-62 Padagis 1 tablet $0.078 — Availability likely —
Nasal Decongestant Maximum Strength, Non-Drowsy 30 mg 46122-0428-62 Amerisource 24 tablets $0.078 — Availability likely —
Leader Nasal Decongestant 30 mg 70000-0002-01 Cardinal 1 tablet $0.078 — Availability likely —
Nasal Decongestant Maximum Strength 30 mg 70677-1017-01 Strategic 24 tablets $0.078 — Availability likely —
Nasal Decongestant D 30 mg 00363-1214-08 Walgreen 24 tablets — — FDA listed —
Sinus Pressure and Congestion Relief Maximum Strength 30 mg 11822-0112-02 Rite 24 tablets — — FDA listed —
Nasal Decongestant Maximum Strength 30 mg 21130-0112-08 Better 24 tablets — — FDA listed —
sinus 30 mg 30142-0613-62 Kroger 1 tablet — — Discontinued —
Sinus Decongestion 30 mg 30142-0641-08 Kroger 24 tablets — — FDA listed —
Topcare Nasal Decongestant Maximum Strength Non Drowsy 30 mg 36800-0432-62 Topco 1 tablet — — FDA listed —
Nasal Decongestant 30 mg 37808-0112-22 H 24 tablets — — FDA listed —
equaline nasal decongestant non drowsy maximum strength 30 mg 41163-0432-67 United 6 tablets — — FDA listed —
nasal decongestant maximum strength non drowsy 30 mg 41250-0432-62 Meijer 1 tablet — — FDA listed —
CareOne Nasal and Sinus Decongestant 30 mg 41520-0881-62 American 12 tablets — — FDA listed —
Sinus and Congestion Non-Drowsy 30 mg 49035-0780-08 Wal-Mart 24 tablets — — FDA listed —
Sudogest 30 mg 50090-1961-00 A-S 28 tablets — — FDA listed —
Sudogest Nasal Decongestant 30 mg 50090-4345-00 A-S 48 tablets — — Discontinued —
pseudoephedrine hydrochloride 30 mg 50090-5615-01 A-S 1 tablet — — FDA listed —
SUDAFED Sinus Congestion 30 mg 50580-0363-01 Kenvue 12 tablets — — FDA listed —
Nasal Decongestant 30 mg 50844-0112-08 L.N.K. 12 tablets — — FDA listed —
Sinus and Nasal Decongestant 30 mg 51316-0121-22 CVS 24 tablets — — FDA listed —
Sinus And Nasal Decongestant 30 mg 51316-0317-62 CVS 12 tablets — — FDA listed —
Nasal Decongestant 30 mg 56062-0432-62 Publix 24 tablets — — FDA listed —
Nasal Decongestant Non-Drowsy 30 mg 59779-0112-08 CVS 24 tablets — — FDA listed —
Nasal Decongestant 30 mg 59779-0432-62 CVS 1 tablet — — FDA listed —
Nasal Decongestant 30 mg 63187-0344-24 Proficient 24 tablets — — FDA listed —
Nasal Decongestant Maximum Strength 30 mg 63868-0802-24 CHAIN 24 tablets — — FDA listed —
Nasal Decongestant Maximum Strength 30 mg 68016-0473-24 Chain 24 tablets — — FDA listed —
pseudoephedrine hydrochloride 30 mg 71205-0197-24 Proficient 1 tablet — — FDA listed —
Sinus Congestion 30 mg 83324-0054-24 Chain 24 tablets — — FDA listed —
pseudoephedrine hydrochloride 30 mg 85766-0049-24 Sportpharm 1 tablet — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
Jan 2019
📍
2026
Currently FDA-listed
7 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerMajor Pharmaceuticals
FDA applicationM012 (OTC MONOGRAPH DRUG)
Labeler code00904
First marketedJan 2019
Product typeHuman Otc Drug
Portfolio630 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 23 words ▾

Uses temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies temporarily relieves sinus congestion and pressure

⏱️ Dosage and Administration 39 words ▾

Directions take every 4-6 hours do not take more than 4 doses in 24 hours adults & children 12 years & over 2 tablets children 6 to under 12 years 1 tablets children under 6 years do not use

⚠️ Warnings 143 words ▾

Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if you have heart disease high blood pressure thyroid disease diabetes trouble urinating due to an enlarged prostate gland When using this product do not exceed recommended dose.

Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur symptoms do not improve within 7 days or occur with a fever If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

🆘 Overdosage 15 words ▾

In case of overdose, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 11 words ▾

Drug Facts Active ingredient (in each tablet) Pseudoephedrine HCl 30 mg

🧪 Inactive Ingredients 33 words ▾

calcium sulfate, carnauba wax, corn starch, croscarmellose sodium, FD&C red #40 lake, FD&C yellow #6 lake, gelatin, kaolin, lactose monohydrate, magnesium stearate, microcrystalline cellulose, shellac, silicon dioxide, stearic acid, sucrose, talc, titanium dioxide.

🎯 Purpose 3 words ▾

Purpose Nasal decongestant

📄 Do Not Use 55 words ▾

Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

📄 Ask a Doctor Before Use If 24 words ▾

Ask a doctor before use if you have heart disease high blood pressure thyroid disease diabetes trouble urinating due to an enlarged prostate gland

📄 When Using This Product 9 words ▾

When using this product do not exceed recommended dose.

📄 Stop Use and Ask a Doctor If 24 words ▾

Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur symptoms do not improve within 7 days or occur with a fever

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breast-feeding, ask a health professional before use.

📄 Keep Out of Reach of Children 6 words ▾

Keep out of reach of children.

📄 Other Information 16 words ▾

Other information Store between 15° - 30°C (59° - 86°F) use by expiration date on package

📄 Questions or Comments 4 words ▾

Questions or comments? 1-800-616-2471

📄 Package Label / Principal Display Panel 47 words ▾

MAJOR ® NDC 0904-6727-60 Non Drowsy SudoGest TM Nasal Decongestant Pseudoephedrine Hydrochloride 30mg FOR PHARMACY USE ONLY. NOT FOR RETAIL SALE. Relieves Nasal and Sinus Congestion due to Colds or Hay Fever without drowsiness Compare to the active ingredient in Sudafed® Sinus Congestion* 100 Tablets Major Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.3K
Units reimbursed last 4 qtrs
56.5K
Gross reimbursed last 4 qtrs
$14.8K
Avg / prescription
$11.26
Avg / unit
$0.2622
Latest quarter Q1 2026
251Rx
Medicaid pays / ea
$0.2622
gross reimbursed
vs
NADAC / ea
$0.0776
acquisition cost
=
Spread
+$0.1846
+238% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
93% FFS
Fee-for-service · 1,226 Rx Managed care · 89 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 34,972 units · 179 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 778 units · 6.6 per 100k residents OH Pennsylvania: 1,163 units · 9.0 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 17,996 units · 46.2 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 1,575 units · 34.8 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
6.6179
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 179 /100k
2 California 46.2 /100k
3 Kentucky 34.8 /100k
4 Pennsylvania 9.0 /100k
5 Ohio 6.6 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for SudoGest (this brand).

Top reported reactions

Systemic Lupus Erythematosus5,337
Pain5,307
Pemphigus5,214
Rheumatoid Arthritis5,213
Abdominal Discomfort5,117
Alopecia5,011
Glossodynia4,787

Reporter sex

10,900 reports
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,961 308
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.